Sorrento Therapeutics (SRNE) Competitors $0.0060 0.00 (0.00%) As of 08/28/2025 03:49 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRNE vs. EVOK, RNAZ, VYNE, AEON, SNOA, CYCN, ADIL, CELZ, TSBX, and ALBTShould you be buying Sorrento Therapeutics stock or one of its competitors? The main competitors of Sorrento Therapeutics include Evoke Pharma (EVOK), TransCode Therapeutics (RNAZ), VYNE Therapeutics (VYNE), AEON Biopharma (AEON), Sonoma Pharmaceuticals (SNOA), Cyclerion Therapeutics (CYCN), Adial Pharmaceuticals (ADIL), Creative Medical Technology (CELZ), Turnstone Biologics (TSBX), and Avalon GloboCare (ALBT). These companies are all part of the "pharmaceutical products" industry. Sorrento Therapeutics vs. Its Competitors Evoke Pharma TransCode Therapeutics VYNE Therapeutics AEON Biopharma Sonoma Pharmaceuticals Cyclerion Therapeutics Adial Pharmaceuticals Creative Medical Technology Turnstone Biologics Avalon GloboCare Sorrento Therapeutics (NASDAQ:SRNE) and Evoke Pharma (NASDAQ:EVOK) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment. Does the media prefer SRNE or EVOK? In the previous week, Evoke Pharma had 3 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 3 mentions for Evoke Pharma and 0 mentions for Sorrento Therapeutics. Evoke Pharma's average media sentiment score of 0.63 beat Sorrento Therapeutics' score of 0.00 indicating that Evoke Pharma is being referred to more favorably in the news media. Company Overall Sentiment Sorrento Therapeutics Neutral Evoke Pharma Positive Which has more risk and volatility, SRNE or EVOK? Sorrento Therapeutics has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, Evoke Pharma has a beta of -0.04, suggesting that its share price is 104% less volatile than the S&P 500. Is SRNE or EVOK more profitable? Sorrento Therapeutics has a net margin of 0.00% compared to Evoke Pharma's net margin of -42.07%. Sorrento Therapeutics' return on equity of 0.00% beat Evoke Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Sorrento TherapeuticsN/A N/A N/A Evoke Pharma -42.07%-99.48%-33.58% Which has higher valuation & earnings, SRNE or EVOK? Evoke Pharma has lower revenue, but higher earnings than Sorrento Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSorrento Therapeutics$60.32M0.05-$572.84MN/AN/AEvoke Pharma$10.25M0.81-$5.35M-$2.56-2.07 Do institutionals & insiders hold more shares of SRNE or EVOK? 0.0% of Sorrento Therapeutics shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by insiders. Comparatively, 2.3% of Evoke Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummarySorrento Therapeutics beats Evoke Pharma on 7 of the 11 factors compared between the two stocks. Get Sorrento Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRNE vs. The Competition Export to ExcelMetricSorrento TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.31M$283.75M$5.78B$9.79BDividend YieldN/AN/A3.95%4.02%P/E RatioN/AN/A31.2726.59Price / Sales0.05538.68428.42155.72Price / CashN/A22.4437.7359.36Price / BookN/A10.1710.046.68Net Income-$572.84M-$115.81M$3.27B$265.59M7 Day PerformanceN/A0.04%1.34%0.66%1 Month PerformanceN/A0.41%6.13%2.64%1 Year PerformanceN/A-14.82%41.90%22.36% Sorrento Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRNESorrento Therapeutics0.621 of 5 stars$0.01flatN/A-33.3%$3.31M$60.32M0.00800EVOKEvoke Pharma0.6944 of 5 stars$5.20-6.0%N/A+20.3%$8.62M$10.25M-2.034Gap DownRNAZTransCode Therapeutics1.9967 of 5 stars$9.79-4.6%$280.00+2,760.1%-99.9%$8.55MN/A0.009Positive NewsVYNEVYNE Therapeutics2.2258 of 5 stars$0.33-2.6%$6.25+1,821.9%-81.7%$8.51M$500K-0.3630AEONAEON Biopharma2.9844 of 5 stars$0.73-5.8%$360.00+49,555.2%-98.9%$8.44MN/A4.035SNOASonoma PharmaceuticalsN/A$4.83-5.1%N/A+2,702.7%$8.36M$14.29M-1.96180CYCNCyclerion Therapeutics2.4974 of 5 stars$2.55+2.4%N/A-4.1%$8.31M$2.17M-3.4530ADILAdial Pharmaceuticals1.8079 of 5 stars$0.38+1.0%$8.00+1,984.4%-59.7%$8.30MN/A-0.3720CELZCreative Medical Technology1.268 of 5 stars$3.19flatN/A-3.1%$8.23M$10K-1.005Gap DownTSBXTurnstone Biologics3.1055 of 5 stars$0.36flat$0.45+26.8%N/A$8.22M$19.31M-0.1782ALBTAvalon GloboCare1.225 of 5 stars$2.13-0.5%N/A-46.5%$8.21M$1.33M-0.115News Coverage Related Companies and Tools Related Companies Evoke Pharma Competitors TransCode Therapeutics Competitors VYNE Therapeutics Competitors AEON Biopharma Competitors Sonoma Pharmaceuticals Competitors Cyclerion Therapeutics Competitors Adial Pharmaceuticals Competitors Creative Medical Technology Competitors Turnstone Biologics Competitors Avalon GloboCare Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRNE) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sorrento Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access